Pharmaceuticals / Drugs
-
Blair Leavitt, MD, CM
Professor
- Genetic brain diseases
- neurodegenerative diseases
- Huntington disease
- frontotemporal dementia
- amyotrophic lateral sclerosis
- ataxia
-
Brenda Lau, MD, FRCPC
Program Director
- Anesthesiology
- pain medicine
- pain interventions
- autonomic nervous system
- rehabilitation
- opioids
- pain training
- point of care
- ultrasound
- community clinics
- regional pain services
- movement rehabilitation
- yoga
- nutrition
- prevention
- post surgical pain
- post trauma pain
- headaches
- back pain
- whiplash
- abdominal
- fibromyalgia
- widespread pain
- neuropathic pain
- chronic disease
- Royal College pain medicine subspecialty
- practice based evidence
- injury prevention
- post surgical care
- non opioid pain services
- myofacial release
- IMS
-
Dr. Mads Daugaard, PhD
Associate Professor
- Cancer Research
- Translational cancer research
- DNA damage response
- Glycobiology
- Cell death
- Experimental therapeutics
- Experimental diagnostics
-
Anthony Phillips, CM
Professor
- Neural plasticity
- learning and memory
- brain health
- motivation
- dementia
- mood disorders
- schizophrenia
-
Bruce Carleton, BSc, PharmD
Professor
- Human drug therapy
- clinical pharmacology
- adverse drug reactions
- side effects
- drug outcomes
- pharmaceuticals
- pediatric drug use
- genetics of drug action
- pharmacogenomics
-
Dieter Brömme, PhD, DSc
Professor
- Proteases in diseases
- osteoporosis
- arthritis
- cardiovascular diseases
- natural products
- drug development
-
Mohsen Sadatsafavi, MD, PhD
Associate Professor
- Epidemiology and Biostatistics
- Decision Analysis
- Clinical Prediction Modeling
- Asthma
- Chronic Obstructive Pulmonary Disease
-
Marcel Bally, MSc, PhD
Professor
- Biochemistry
- pharmacology/toxicology
- drug formulations
- nanotechnology
- preclinical cancer models
- preclinical safety studies under Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP)
-
Marcel Bally, MSc, PhD
Professor
- Biochemistry
- pharmacology/toxicology
- drug formulations
- nanotechnology
- preclinical cancer models
- preclinical safety studies under Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP)